The JUPITER Trial States the Benefits of Statin Medications Outweigh the Risks of Developing Diabetes
An analysis of the JUPITER trial, published by the Lancet in August of 2012, stated that the benefits of statin medications outweigh the risks of developing diabetes, even in participants at high risk for developing the disease.
These conclusion were based primarily on a calculation of avoided deaths versus new cases of diabetes. It should be noted that this study was funded by AstraZeneca. AstraZeneca is the manufacturer of Crestor (rosuvastatin), which is another cholesterol medication in the statin drug class, and the medication used in the trial.
Whether this extends to Zocor, Lipitor, and other statins, is unclear. The list of Zocor side effects, in addition to diabetes, encompasses liver damage from Zocor, muscle injury and rhadomyolysis.
Statistically, the numbers favor statin drugs
Diabetes is a dangerous and serious condition. It entails permanent lifestyle changes and can lead to painful injuries and death. For many, the benefits of medication may never outweigh the risk of developing diabetes. Statistically speaking, the numbers favor statin drugs. The JUPITER trial, for example, found that for high-risk individuals, statins were associated with a 39% reduction in primary endpoints and a 17% reduction in total mortality. By comparison, they caused a 28% increase in diabetes. For trial participants without any risk factors for diabetes, statins were found to reduce primary endpoints by 52%, death by 22%, and to have no increase in diabetes risk.
Statin drugs are related to a range of side effects in addition to the risk of diabetes
In addition to an elevated risk of diabetes, statin drugs are also associated with a range of other side effects. The FDA defines affected statin drugs as: Altoprev (lovastatin extended-release). Crestor (rosuvastatin), Lescol (fluvastatin), Lipitor (atorvastatin), Livalo (pitavastatin), Mevacor (lovastatin), Pravachol (pravastatin), and Zocor (simvastatin), as well as combination medications Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release), and Vytorin (simvastatin/ezetimibe).
For patients on simvastatin, one of the most serious dangers in muscle injury from Zocor, including rhabdomyolysis. Additionally, the drug is associated with memory loss and liver injury. Patients suffering from any of side effects should contact an attorney for an evaluation of his or her claims. Experienced Zocor attorneys are best qualified to evaluate each complaint on a case-by-case basis.
The purpose of the published analysis
The published analysis was designed to, “address the balance of vascular benefits and diabetes hazard of statin use.” To do so, researchers analyzed information for the JUPITER study, a randomized, double-blind trial of 17,603 men and women. Study participants had no history of diabetes or cardiovascular disease, and were assigned either a placebo or rosuvastatin 20mg (Crestor) for up to five years. The primary endpoints for each participant included stroke, myocardial infarction, or cardiovascular death, while secondary endpoints extended to venous thromboembolism, incident physician-reported diabetes, and all-cause mortality.Invalid tag specified, please contact administrator.